During the past decade, National Cancer Inst. conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 8 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Cancer Inst." #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Immunovative Therapies, Ltd." with 3 trials sponsored, "Genentech, Inc." with 2 trials sponsored, "Chulalongkorn University" with 1 trials sponsored and "FeRx" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Cancer Inst." #1 collaborator was "Genentech, Inc." with 3 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "Bumrungrad International Hospital" with 1 trials as a collaborator, "Cancer International Research Group (CIRG)" with 1 trials as a collaborator and "Chulalongkorn University" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "National Cancer Inst." are "Breast Cancer" (3 trials), "Non-Small Cell Lung Cancer" (2 trials), "Adenocarcinoma" (1 trials), "B-cell Lymphoma" (1 trials) and "Cancer of Head and Neck" (1 trials). Many other conditions were trialed in "National Cancer Inst." in a lesser frequency.

Most popular intervention types in "National Cancer Inst." are "Drug" (13 trials), "Biological" (7 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (4 trials), "Docetaxel" (3 trials), "Placebo" (3 trials), "5-Fluorouracil" (2 trials) and "Bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "National Cancer Inst." are 16 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "National Cancer Inst.". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in National Cancer Inst., undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in National Cancer Inst., 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".